Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00299416 · ClinicalTrials.gov registry record · Phase 1

Caffeinol Hypothermia Protocol

A Phase 1 study of Acute Ischemic Stroke, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT00299416 is a Phase 1 study of Acute Ischemic Stroke that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 30 participants, below the 351-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00299416, a Phase 1 study of Acute Ischemic Stroke, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Caffeinol is a combination of caffeine and alcohol. The amount given is about the same as 1-2 glasses of wine and 3-4 cups of coffee. The patient receives a one time dose given over two hour while being cooled to 34.5 C.

Conditions Studied

Interventions

  • DRUG Caffeinol
  • PROCEDURE hypothermia

Study Locations (1)

Texas

  • Memorial Hermann Hospital - Medical Center - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2003-02
Est. Completion 2009-08
Phase Phase 1

What the Registry Record Tells You About NCT00299416

The ClinicalTrials.gov registry entry for NCT00299416 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (91% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which Caffeinol is the first listed.

NCT00299416 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00299416 about?

NCT00299416 is a clinical study titled "Caffeinol Hypothermia Protocol". Caffeinol is a combination of caffeine and alcohol. The amount given is about the same as 1-2 glasses of wine and 3-4 cups of coffee. The patient receives a one time dose given over two hour while being cooled to 34.5 C.

What is the current status of trial NCT00299416?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2003-02. Estimated completion is 2009-08.

What conditions does trial NCT00299416 study?

This clinical trial studies the following conditions: Acute Ischemic Stroke.

What interventions are being tested in trial NCT00299416?

The interventions under investigation include: Caffeinol (DRUG), hypothermia (PROCEDURE).

Who is sponsoring clinical trial NCT00299416?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00299416 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.